Introduction

Nolla Health, a Utah-based startup, is rolling out an AI-driven system that evaluates acne through a selfie and generates a prescription. The service is now active in Utah, marking a first in the U.S. for AI-initiated pharmaceutical recommendations.

What Happened

The Utah state government has approved Nolla Health's AI to scan users' faces and autonomously write acne treatment prescriptions. The pilot launches at $4.99 monthly, open to Utah residents 18+ with mild-to-moderate acne. Two physicians sign off on the first 100 scripts; after 500, doctors review 10% of new prescriptions monthly, plus any flagged for side effects or escalation. The AI can currently recommend eight different topical treatments and will refer users to a human clinician if it isn't confident in a choice. Nolla frames the tool as a way to offload routine cases so dermatologists can focus on complex patients.

Why This Matters

This move represents the first known instance in the U.S. where AI has been authorized to issue initial prescriptions rather than just renew existing ones. It highlights the growing tension between automation efficiency and patient safety in telehealth, and sets a precedent for how states might regulate AI-driven drug authorization. If successful, similar models could expand to other conditions or states, though regulatory and ethical hurdles remain.

Key Takeaways

  • Program limited to Utah with a $4.99 monthly subscription
  • Eligibility requires Utah residency, age 18+, and mild-to-moderate acne
  • AI analyzes a selfie and suggests one of eight treatment options
  • Physician oversight begins with sign-off on the first 100 prescriptions, then shifts to monthly 10% reviews
  • AI redirects users to a human clinician if it cannot confidently select a treatment
  • Nolla positions the tool as a complement to, not a replacement for, dermatologists

Conclusion

Nolla Health's AI prescription pilot is a significant test case for AI in primary care. It could streamline access to common dermatological treatments, but its success will depend on safety outcomes, patient trust, and how regulators weigh automation against medical oversight. The coming months will reveal whether this model scales or prompts tighter restrictions on AI-authorized medications.